UCB BioPharmaceuticals the global biopharmaceutical company focuses on developing targeted small molecules and monoclonal antibodies for severe immunological and neurological diseases.
However, UCB intersects with vaccination programs and clinical trials in several distinct ways:
1. Mandatory Vaccinations Required for UCB Drug Clinical Trials
Because UCB manufactures potent immunomodulators and complement inhibitors, participants in their clinical trials (and patients taking their approved drugs) must strictly adhere to specific vaccination protocols.
•ZILBRYSQ® (zilucoplan): This approved daily subcutaneous injection targets generalized Myasthenia Gravis (gMG). As a complement component 5 (C5) inhibitor, it significantly increases a patient's risk for life-threatening meningococcal infections.
•The Trial/Treatment Rule: Clinical trial participants and patients must complete or update meningococcal vaccines (protecting against serogroups A, C, W, Y, and B) at least two weeks before receiving their first dose. If urgent treatment is required before the vaccine takes effect, they must receive prophylactic antibiotics.
2. Active Clinical Trials and Drug Pipeline
UCB's clinical pipeline relies heavily on biologics, monoclonal antibodies (mAbs), and targeted small molecules rather than traditional vaccine platforms. Major active clinical trial areas include:
•Neurology (Parkinson’s Disease): UCB is collaborating with Novartis to co-develop UCB0599. This is an oral, small-molecule alpha-synuclein misfolding inhibitor currently undergoing Phase 2 clinical trials to determine if it can slow disease progression. They are also testing UCB7853, an anti-alpha-synuclein antibody, in Phase 1 trials.
•Advanced Immunology: In mid-2026, UCB closed a $2.2 billion acquisition of Candid Therapeutics, integrating multi-specific T-cell engager (TCE) antibodies into their pipeline. Their lead asset, cizutamig, is being evaluated to deplete pathogenic B-cells in severe autoimmune disorders.
•Respiratory & Dermatology: UCB is evaluating galvokimig, a multi-specific antibody targeting IL-13, IL-17A, and IL-17F. It is currently in clinical testing for severe atopic dermatitis and is expanding into Phase 2a proof-of-concept studies for Chronic Obstructive Pulmonary Disease (COPD).